Generalized necrobiotic xanthogranuloma successfully treated with lenalidomide.
Necrobiotic xanthogranuloma (NXG) presents a therapeutic challenge to clinicians. Generalized NXG has limited treatment options. A patient presented to the authors with generalized NXG associated with monoclonal gammopathy of unknown significance (MGUS), a plasma cell dyscrasia considered to be a precursor to multiple myeloma. The patient was treated with lenalidomide, a derivative of thalidomide with efficacy in treatment of multiple myeloma. Resolution of paraproteinemia was associated with resolution of NXG.
Department of Dermatology, University of Texas Medical School at Houston, Houston, TX, USA.
Sirunya
S
Silapunt
Susan Y
SY
Chon
D000368:Aged; D000369:Aged, 80 and over; D003907:Dexamethasone / Q000627:therapeutic use; D006099:Granuloma / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D000077269:Lenalidomide; D008297:Male; D008998:Monoclonal Gammopathy of Undetermined Significance / Q000188:drug therapy; D017441:Necrobiotic Disorders / Q000188:drug therapy* / Q000473:pathology; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D013792:Thalidomide; D003907:Dexamethasone; D000077269:Lenalidomide